Mercer Global Advisors
NVO

Mercer Global Advisors’s Novo Nordisk NVO Stock Holding History

Mercer Global Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.62M Buy
158,921
+9,074
+6% +$390K 0.01% 672
2026
Q1 		$5.51M Sell
149,847
-14,643
-9% -$694K 0.01% 727
2025
Q4 		$8.37M Buy
164,490
+2,599
+2% +$133K 0.01% 544
2025
Q3 		$8.98M Sell
161,891
-7,012
-4% -$410K 0.02% 487
2025
Q2 		$11.7M Sell
168,903
-2,145
-1% -$146K 0.02% 354
2025
Q1 		$11.9M Sell
171,048
-22,970
-12% -$1.9M 0.03% 327
2024
Q4 		$16.7M Sell
194,018
-27,011
-12% -$2.92M 0.04% 249
2024
Q3 		$26.1M Buy
221,029
+16,448
+8% +$2.19M 0.06% 171
2024
Q2 		$29.2M Buy
204,581
+8,030
+4% +$1.06M 0.08% 149
2024
Q1 		$25.5M Sell
196,551
-6,255
-3% -$745K 0.07% 164
2023
Q4 		$21M Buy
202,806
+12,430
+7% +$1.23M 0.06% 187
2023
Q3 		$17.3M Buy
190,376
+2,052
+1% +$181K 0.07% 186
2023
Q2 		$15.2M Buy
188,324
+19,014
+11% +$1.55M 0.06% 207
2023
Q1 		$13.5M Sell
169,310
-4,356
-3% -$309K 0.06% 223
2022
Q4 		$11.8M Sell
173,666
-20,954
-11% -$1.23M 0.06% 241
2022
Q3 		$9.7M Sell
194,620
-3,830
-2% -$205K 0.06% 231
2022
Q2 		$11.1M Buy
198,450
+18,960
+11% +$1.05M 0.07% 207
2022
Q1 		$9.97M Sell
179,490
-22,926
-11% -$1.18M 0.06% 229
2021
Q4 		$11.3M Buy
202,416
+4,674
+2% +$253K 0.07% 203
2021
Q3 		$9.49M Buy
197,742
+19,928
+11% +$963K 0.07% 237
2021
Q2 		$7.45M Buy
177,814
+7,460
+4% +$289K 0.06% 258
2021
Q1 		$5.74M Buy
170,354
+2,264
+1% +$80.6K 0.05% 274
2020
Q4 		$5.87M Buy
168,090
+4,262
+3% +$147K 0.07% 204
2020
Q3 		$5.69M Buy
163,828
+47,068
+40% +$1.57M 0.09% 179
2020
Q2 		$3.82M Buy
116,760
+30,836
+36% +$984K 0.07% 203
2020
Q1 		$2.59M Buy
85,924
+33,298
+63% +$991K 0.06% 265
2019
Q4 		$1.52M Buy
52,626
+870
+2% +$24.1K 0.03% 407
2019
Q3 		$1.34M Buy
51,756
+6,806
+15% +$172K 0.03% 403
2019
Q2 		$1.15M Buy
44,950
+2,394
+6% +$59.2K 0.03% 426
2019
Q1 		$1.11M Buy
+42,556
New +$1.05M 0.04% 386

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Mercer Global Advisors's NVO Position: Q2 2026 in Review

Mercer Global Advisors increased its Novo Nordisk (NVO) stake by 6.1% in Q2 2026, buying an estimated $390K and bringing the position to 158,921 shares worth $7.62M. The position accounts for 0.01% of the portfolio, ranked #672.

Mercer Global Advisors first reported a position in NVO in Q1 2019 and has held it in 30 quarters since. The position peaked at $29.2M in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Mercer Global Advisors held 158,921 shares of Novo Nordisk worth $7.62M as of Q2 2026.
  • Mercer Global Advisors bought 9,074 Novo Nordisk shares in Q2 2026, an estimated $390K.
  • Novo Nordisk made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #672 holding.
  • Mercer Global Advisors first reported a position in Novo Nordisk in Q1 2019 and has held it in 30 quarters since.
  • Mercer Global Advisors's Novo Nordisk position peaked at $29.2M in Q2 2024.
  • 1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.